The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIq-ai Ltd Regulatory News (IQAI)

Share Price Information for Iq-ai Ltd (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.55
Bid: 1.50
Ask: 1.60
Change: -0.10 (-6.06%)
Spread: 0.10 (6.667%)
Open: 1.65
High: 1.65
Low: 1.55
Prev. Close: 1.55
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Start of Trading on the OTCQB Venture Market

1 Sep 2021 10:00

RNS Number : 3752K
IQ-AI Limited
01 September 2021
 

September 1, 2021

IQ-AI Limited

("IQ-AI" or the "Company")

 

IQ-AI shares to commence trading on the OTCQB Venture Market in the United States

 

IQ-AI Limited (LSE: IQAI) is pleased to announce that the Company's ordinary shares will today begin trading on the OTCQB Venture Market ("OTCQB") in the United States, under the ticker symbol "IQAIF".

 

The Company's objective in listing its shares on the OTCQB is to provide more efficient access to a new and materially larger pool of prospective US investors. The Directors believe that IQ-AI's OTCQB listing will enable the Company to engage with a significant network of US investors, data distributors and media partners, ensuring that US investors have access to the same level of information and disclosure that is available to investors in the United Kingdom.

 

The OTCQB trading facility is provided through OTC Markets Group Inc, located in New York. OTC Markets Group Inc. operates the world's largest electronic interdealer quotation system for US broker dealers and offers multiple media channels to increase the visibility of OTC-listed companies. Independent studies show that trading on the OTCQB by an international company offers a positive effect on the liquidity of its shares.

 

Trading on the OTCQB market will have no impact on the IQ-AI ordinary shares admitted to listing on the London Stock Exchange's Main Market under the symbol "IQAI", and no new ordinary shares have been admitted as part of the OTCQB listing. The Company will continue to rely on the announcements and disclosures it makes to the London Stock Exchange and has no Sarbanes-Oxley or SEC reporting requirements.

 

IQ-AI CEO, Trevor Brown, commented:

 

"The United States is home to some of the world's most influential medical technology investors. By joining OTCQB, we now have an effective platform from which to reach a significantly larger investor audience and we look forward to providing investors in both the UK and the United States with regular progress updates at this exciting and pivotal time for the Company."

 

Jonathan Dickson, VP of International Corporate Services at OTC Markets, said:

 

"Congratulations to IQ-AI Ltd on joining the OTCQB Venture Market. We are pleased to support innovative and entrepreneurial international companies seeking to strengthen transparency and to provide better access to disclosure and trading for investors in the United States. Cross-trading on OTCQB in the U.S will enable IQ-AI, which is listed on the London Stock Exchange's Main Market, to diversify its investor base and to expand its global engagement even further."

 

The Company would like to thank Nikolaos Galanopoulos of Galanopoulos & Company, the corporate securities law firm that acted as Sponsor for the Company's application to commence cross-trading on the OTCQB.

 

The Directors of the Company accept responsibility for the contents of this announcement.

 

IQ-AI Limited

Trevor Brown/Dr Qu Li/Vinod Kaushal

 

0207 469 0930

 

Peterhouse Capital Limited

Lucy Williams/Heena Karani

 

0207 220 9797

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDDZGGLRMMGMZG
Date   Source Headline
1st Oct 20197:01 amRNSStoneChecker USA Market Introduction
1st Oct 20197:00 amRNSIssue of Equity
30th Sep 201911:05 amRNSSecond Price Monitoring Extn
30th Sep 201911:00 amRNSPrice Monitoring Extension
27th Sep 20197:00 amRNSFDA Clearance to Market for StoneChecker Software
16th Sep 20199:34 amRNSReplacement - Half Yearly Report to 30 June 2019
16th Sep 20197:00 amRNSHalf-year Report
4th Sep 20197:00 amRNSGrant Award
6th Aug 20197:00 amRNSCompletion of Placing and Conversion of Loan Notes
5th Aug 20192:05 pmRNSSecond Price Monitoring Extn
5th Aug 20192:00 pmRNSPrice Monitoring Extension
9th Jul 20197:00 amRNSUpdate on Gadolinium Free Imaging Project
26th Jun 20197:00 amRNSPlacing
24th Jun 20192:52 pmRNSHolding(s) in Company
20th Jun 20194:40 pmRNSSecond Price Monitoring Extn
20th Jun 20194:35 pmRNSPrice Monitoring Extension
12th Jun 20197:00 amRNSBusiness Development Agreement with CorTechs Labs
6th Jun 201911:49 amRNSResult of AGM
29th May 201911:51 amRNSIssue of Convertible Loan Notes - Correction
29th May 20198:22 amRNSIssue of Convertible Loan Notes
17th May 201912:00 pmRNSExtension of Loan Notes Redemption Date
9th May 20191:30 pmRNSNotice of AGM
9th May 201912:13 pmRNSHolding(s) in Company
30th Apr 201912:00 pmRNSPublication of Annual Report
2nd Apr 20197:00 amRNSImaging Biometrics Update
11th Mar 20197:00 amRNSIssue of Convertible Loan Notes
8th Feb 201910:29 amRNSBusiness Update
2nd Jan 201912:20 pmRNSHolding(s) in Company
13th Dec 20189:00 amRNSPrice Monitoring Extension
13th Dec 20187:00 amRNSStoneChecker 510k Update
11th Dec 20187:00 amRNSInstallation at Barrow Neurological Institute
28th Nov 20187:00 amRNSImaging Biometrics® Update
16th Nov 20187:00 amRNSFirst Commercial Sale of StoneChecker Software
22nd Oct 20187:00 amRNSIQ-AI files patent for Contrast-Free Imaging
4th Oct 20182:58 pmRNSResult of EGM and Change of Name
27th Sep 20187:00 amRNSIB announce agreement to develop a diagnostic tool
18th Sep 20187:00 amRNSProposed name change and notice of EGM
11th Sep 20189:00 amRNSDirector/PDMR Shareholding
11th Sep 20187:00 amRNSDirector/PDMR Shareholding
10th Sep 20187:00 amRNSHalf-year Report
6th Aug 20182:51 pmRNSHolding(s) in Company
6th Aug 20187:00 amRNSAppointment of CEO to the Operating Subsidiaries
1st Aug 20184:28 pmRNSPublication of a Prospectus
31st Jul 20183:54 pmRNSResult of AGM and GM
18th Jul 20181:24 pmRNSNon Regulatory - Vox Markets Podcast
18th Jul 20188:57 amRNSHolding(s) in Company
17th Jul 20187:00 amRNSECOG-ACRIN TO PROCESS CLINICAL TRIAL DATA USING IB
16th Jul 20187:00 amRNSPlacing, Notice of AGM and GM
2nd Jul 20188:34 amRNSMedimsight and IB Enter into Partnership
13th Jun 20187:00 amRNSImaging Biometrics and QMENTA announce partnership

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.